300,500 Shares in Bausch + Lomb Co. (NYSE:BLCO) Bought by Barclays PLC

Barclays PLC bought a new stake in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 300,500 shares of the company's stock, valued at approximately $5,797,000. Barclays PLC owned about 0.09% of Bausch + Lomb as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in BLCO. Clearline Capital LP grew its holdings in Bausch + Lomb by 136.8% in the 2nd quarter. Clearline Capital LP now owns 712,055 shares of the company's stock worth $10,339,000 after acquiring an additional 411,404 shares during the last quarter. Whitebox Advisors LLC increased its holdings in Bausch + Lomb by 28.2% during the 2nd quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company's stock valued at $22,447,000 after purchasing an additional 339,643 shares during the period. Point72 DIFC Ltd purchased a new stake in Bausch + Lomb in the 3rd quarter worth approximately $4,331,000. Point72 Asset Management L.P. increased its stake in shares of Bausch + Lomb by 31.0% during the second quarter. Point72 Asset Management L.P. now owns 647,156 shares of the company's stock valued at $9,397,000 after buying an additional 153,000 shares during the period. Finally, Point72 Europe London LLP boosted its holdings in Bausch + Lomb by 28.9% in the second quarter. Point72 Europe London LLP now owns 653,492 shares of the company's stock valued at $9,489,000 after acquiring an additional 146,583 shares in the last quarter. Hedge funds and other institutional investors own 11.07% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BLCO shares. Morgan Stanley cut shares of Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 price target on the stock. in a research report on Monday, December 2nd. Royal Bank of Canada upped their target price on Bausch + Lomb from $20.00 to $23.00 and gave the stock an "outperform" rating in a report on Tuesday, October 22nd. Bank of America restated an "underperform" rating and issued a $18.00 target price on shares of Bausch + Lomb in a research note on Thursday, December 12th. Citigroup cut Bausch + Lomb from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $24.00 to $22.00 in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus raised their price objective on Bausch + Lomb from $16.00 to $19.00 and gave the company a "hold" rating in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Bausch + Lomb currently has a consensus rating of "Hold" and a consensus target price of $20.58.

Bausch + Lomb Stock Up 0.3 %

BLCO stock traded up $0.05 during midday trading on Friday, hitting $18.00. The company's stock had a trading volume of 401,500 shares, compared to its average volume of 558,707. The firm's 50-day moving average is $19.81 and its 200-day moving average is $17.60. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. Bausch + Lomb Co. has a 12 month low of $13.16 and a 12 month high of $21.69. The company has a market cap of $6.34 billion, a PE ratio of -17.14, a P/E/G ratio of 1.74 and a beta of 0.43.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The company had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.17 billion. During the same period last year, the firm posted $0.22 earnings per share. Bausch + Lomb's revenue was up 18.8% compared to the same quarter last year. On average, equities research analysts forecast that Bausch + Lomb Co. will post 0.6 earnings per share for the current fiscal year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.